DCT and melanoma: The most extensively studied multi-peptide pulsed DC vaccine is ICT-107, which consists of autologous DCs pulsed with six synthetic peptides: HLA-A1-restricted melanoma-associated antigen-1 (MAGE-1) and antigen isolated from immunoselected melanoma-2 (AIM-2), as well as HLA-A2-restricted human EGFR-2 (Her2/neu), tyrosine-related protein-2 (TRP-2), glycoprotein 100 (gp100), and IL-13 receptor alpha 2 (82).